Ketamine Troches vs Nasal Ketamine for Migraine Care

Ketamine troches and nasal ketamine are not interchangeable migraine treatments. Both routes may appear in specialist discussions of difficult-to-treat migraine, but the evidence is limited, protocols vary, and neither compounded ketamine troches nor compounded racemic ketamine nasal spray is an FDA-approved migraine product. For an at-home patient, the practical difference is often less about convenience and more about whether a headache specialist and ketamine prescriber can explain the treatment goal, monitoring plan, and stop rules.

In 2026, the clearest starting point is this: use a route only within a prescriber-supervised plan, and do not convert a troche instruction into a nasal-spray instruction, or the reverse. This article is educational, not medical advice. Your own prescriber should decide whether ketamine has a role in your migraine care, how it fits with your migraine medicines, and whether home treatment is appropriate.

What the migraine evidence actually supports

The evidence does not establish ketamine troches as a standard migraine treatment. A 2023 retrospective study from a single academic headache center reported that some patients with refractory chronic migraine used compounded intranasal ketamine and reported benefit, but the authors also described adverse events and emphasized the need for prospective controlled trials. Read the study directly in The Journal of Headache and Pain before treating its findings as a general recommendation.

Older research has also explored intranasal ketamine for prolonged migraine aura. For example, a small randomized trial published in Neurology evaluated intranasal ketamine for migraine with prolonged aura, which is a narrower question than routine treatment of migraine pain at home. These studies can inform a clinician-patient discussion, but they do not prove that one route works better for every person with migraine.

According to the 2023 single-center retrospective study, 169 adults with refractory chronic migraine were prescribed intranasal ketamine, a figure that describes that clinic population and does not measure effectiveness for the broader migraine population. A retrospective report can identify patterns worth testing, but it cannot control for selection, other treatments, or placebo effects the way a well-designed randomized trial can.

If migraine is your main concern, ask your clinician to distinguish three separate questions: whether ketamine is being considered for an acute attack, for a difficult chronic pattern, or for a coexisting condition such as depression or pain. The answer changes the evidence base and the safety plan.

How the at-home routine differs

A troche is a compounded dosage form designed to dissolve in the mouth. Your prescriber may call the intended route sublingual, meaning under the tongue, or buccal, meaning between the gum and cheek. Do not chew, swallow early, split, redose, or change the hold time unless your prescribing clinician has given you specific instructions. The handling routine affects exposure, and copying advice from another patient can create an avoidable safety problem.

A nasal product has different practical variables. Nasal congestion, nosebleeds, irritation, recent nasal surgery, and spray technique can matter to absorption or tolerability. A patient who dislikes the mouth feel of a troche may prefer the concept of a spray, but that preference does not answer whether the nasal route is appropriate for their migraine pattern or medical history.

For troche users, the home session should be planned rather than squeezed between errands. Review our guide to the ketamine troche onset, peak, and duration timeline, then follow only the timeline and transportation restrictions your own prescriber gives you. If a clinician includes home blood-pressure checks in your protocol, use the same method and thresholds they specify. This guide on how to check blood pressure before a troche session can help you prepare questions, but it does not replace their directions.

Storage also differs by product and pharmacy. Keep troches in their labeled container, away from children, pets, heat, and moisture, and follow the pharmacy's beyond-use date rather than assuming every compounded product has the same shelf life. A compounding pharmacy can explain the label, storage conditions, and how to handle a damaged or delayed shipment.

Who may fit each discussion, and who should pause

Troches may be worth discussing when a licensed clinician already believes a supervised at-home sublingual protocol is appropriate and you can reliably follow preparation, monitoring, and follow-up requirements. That does not mean troches are a first-choice migraine treatment. A headache specialist should first make sure your diagnosis, acute-treatment plan, preventive plan, medication-overuse risk, and red-flag symptoms have been reviewed.

Nasal ketamine may be a topic when a headache clinic uses a documented protocol for a specific, refractory population and can explain why the nasal route is being considered. It is not a workaround for a prescriber who cannot support safe at-home ketamine care. If a clinic mentions Spravato, ask plainly whether it is being considered for an FDA-approved depression indication, an off-label indication, or not at all. Our comparison of Spravato vs ketamine troches effectiveness explains why the product and indication matter.

Either route needs added caution, or may be unsuitable, if you cannot follow the no-driving and observation instructions, have uncontrolled health issues relevant to ketamine safety, have a history your prescriber believes raises misuse risk, or are experiencing a new severe headache with neurological warning signs. Seek urgent medical assessment for sudden severe headache, new weakness, confusion, fainting, seizure, fever with stiff neck, or other emergency symptoms. Do not use an at-home ketamine session to self-manage a possible emergency.

Cost, coverage, and choosing a legitimate care pathway

Out-of-pocket cost is often a deciding factor because compounded ketamine is commonly excluded from insurance coverage, while migraine care may involve separate charges for evaluation, follow-up, medication, and pharmacy shipping. Do not assume a nasal route is covered because it is a spray, or that Spravato coverage applies to migraine. Coverage decisions depend on the product, diagnosis, plan rules, and network status. Start with is ketamine treatment covered by insurance and confirm the details with your insurer and clinician's billing team.

A legitimate pathway begins with an evaluation by a licensed clinician who can review your migraine history, medications, contraindications, mental health history, and home-safety setup. They should tell you the exact product, route, pharmacy, follow-up cadence, and what would make them stop or change the plan. Be cautious of any service that frames ketamine as a guaranteed migraine fix, skips medical screening, or leaves you to decide your own dosing routine.

Infusion care may be considered in some difficult pain or headache contexts because it provides direct on-site monitoring, but it is less convenient and can cost more. If that comparison is relevant to you, read ketamine troches vs infusion therapy for chronic pain. For a formulation-focused comparison, see ketamine troche vs rapid dissolve tablet. Neither page can determine your route, but both can help you ask more precise questions at an appointment.